作者
Moo-Yong Rhee, Kyung-Jin Kim, Sang-Hyun Kim, Young Won Yoon, Seung-Woon Rha, Soon Jun Hong, Choong-Hwan Kwak, Weon Kim, Chang-Wook Nam, Tae-Ho Park, Taek-Jong Hong, Sungha Park, Youngkeun Ahn, Namho Lee, Hui-Kyung Jeon, Dong Woon Jeon, Kyoo-Rok Han, Keon-Woong Moon, In-Ho Chae, Hae-Young Kim, Hyo-Soo Kim
发表日期
2019/12/1
期刊
Clinical Therapeutics
卷号
41
期号
12
页码范围
2571-2592
出版商
Elsevier
简介
Purpose
The goal of this study was to compare the lipid-lowering efficacy of the combination of ezetimibe and low- or intermediate-intensity statin therapy versus that of high-intensity statin monotherapy.
Methods
This study is a post hoc analysis of an 8-week, randomized, double-blind, Phase III trial. Patients who had hypercholesterolemia and required lipid-lowering treatment were randomly assigned to 1 of 6 treatment groups: rosuvastatin 5 mg (R5, n = 68), rosuvastatin 10 mg (R10, n = 67), rosuvastatin 20 mg (R20, n = 69), and ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10, n = 67), rosuvastatin 10 mg (R10 + E10, n = 68), and rosuvastatin 20 mg (R20 + E10, n = 68) daily. The effects of coadministration of ezetimibe and a low dose of rosuvastatin on lipid parameters and the target achievement rate were compared between the R5 + E10 and R10 treatment groups, the R5 + E10 and R20 treatment …
学术搜索中的文章
MY Rhee, KJ Kim, SH Kim, YW Yoon, SW Rha… - Clinical Therapeutics, 2019